These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34720461)

  • 1. Resiliency of on-demand multimodal transit systems during a pandemic.
    Auad R; Dalmeijer K; Riley C; Santanam T; Trasatti A; Van Hentenryck P; Zhang H
    Transp Res Part C Emerg Technol; 2021 Dec; 133():103418. PubMed ID: 34720461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An estimation of the effects of social distancing measures on transit vehicle capacity and operations.
    Kamga C; Tchamna R; Vicuna P; Mudigonda S; Moghimi B
    Transp Res Interdiscip Perspect; 2021 Jun; 10():100398. PubMed ID: 34514373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On bus ridership and frequency.
    Berrebi SJ; Joshi S; Watkins KE
    Transp Res Part A Policy Pract; 2021 Jun; 148():140-154. PubMed ID: 36569980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-Ridership: A web tool for reprogramming public transportation fleets to minimize COVID-19 transmission.
    Imani S; Vahed M; Satodia S; Vahed M
    SoftwareX; 2023 May; 22():101350. PubMed ID: 36969748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pandemic transit: examining transit use changes and equity implications in Boston, Houston, and Los Angeles.
    Paul J; Taylor BD
    Transportation (Amst); 2022 Oct; ():1-29. PubMed ID: 36340503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitigating Increased Driving after the COVID-19 Pandemic: An Analysis on Mode Share, Travel Demand, and Public Transport Capacity.
    Ciuffini F; Tengattini S; Bigazzi AY
    Transp Res Rec; 2023 Apr; 2677(4):154-167. PubMed ID: 37153203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 public transit precautions: Trade-offs between risk reduction and costs.
    Hanig L; Harper CD; Nock D
    Transp Res Interdiscip Perspect; 2023 Mar; 18():100762. PubMed ID: 36743259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceived risks of transit use during COVID-19: Correlates and strategies from a case study in El Paso, Texas.
    Bian JJ; Zhong S; Towne SD; Lee C; Ory MG; Li W
    J Transp Health; 2022 Dec; 27():101491. PubMed ID: 36059855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What can bring transit ridership back: An econometric study on the potential of usage incentives and operational policies in the Greater Toronto Area.
    Mashrur SM; Wang K; Lavoie B; Habib KN
    Transp Res Part F Traffic Psychol Behav; 2023 May; 95():18-35. PubMed ID: 37035633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating COVID-19 health risks into crowding costs for transit schedule planning.
    Devasurendra KW; Saidi S; Wirasinghe SC; Kattan L
    Transp Res Interdiscip Perspect; 2022 Mar; 13():100522. PubMed ID: 34957387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disparities in the Impacts of the COVID-19 Pandemic on Public Transit Ridership in Austin, Texas, U.S.A.
    Jiao J; Hansen K; Azimian A
    Transp Res Rec; 2023 Apr; 2677(4):287-297. PubMed ID: 37153206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impacts of COVID-19 pandemic on public transit demand in the United States.
    Liu L; Miller HJ; Scheff J
    PLoS One; 2020; 15(11):e0242476. PubMed ID: 33206721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facing the future of transit ridership: shifting attitudes towards public transit and auto ownership among transit riders during COVID-19.
    Palm M; Allen J; Zhang Y; Tiznado-Aitken I; Batomen B; Farber S; Widener M
    Transportation (Amst); 2022 Oct; ():1-27. PubMed ID: 36340501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analyzing equity impacts of transit fare changes: Case study of Alameda-Contra Costa Transit, California.
    Nuworsoo C; Golub A; Deakin E
    Eval Program Plann; 2009 Nov; 32(4):360-8. PubMed ID: 19616299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating public transit agency responses to the Covid-19 pandemic in seven U.S. regions.
    Karner A; LaRue S; Klumpenhouwer W; Rowangould D
    Case Stud Transp Policy; 2023 Jun; 12():100989. PubMed ID: 36910544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing public transit during a pandemic: The trade-off between safety and mobility.
    Luo Q; Gee M; Piccoli B; Work D; Samaranayake S
    Transp Res Part C Emerg Technol; 2022 May; 138():103592. PubMed ID: 35340721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mining urban sustainable performance: Spatio-temporal emission potential changes of urban transit buses in post-COVID-19 future.
    Sui Y; Zhang H; Shang W; Sun R; Wang C; Ji J; Song X; Shao F
    Appl Energy; 2020 Dec; 280():115966. PubMed ID: 33052166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canadian transit agencies response to COVID-19: Understanding strategies, information accessibility and the use of social media.
    Diaz F; Abbasi SJ; Fuller D; Diab E
    Transp Res Interdiscip Perspect; 2021 Dec; 12():100465. PubMed ID: 34604734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covid-19 pandemic impacts on essential transit riders: Findings from a U.S. Survey.
    He Q; Rowangould D; Karner A; Palm M; LaRue S
    Transp Res D Transp Environ; 2022 Apr; 105():103217. PubMed ID: 35194378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Data-driven analysis of the impact of COVID-19 on Madrid's public transport during each phase of the pandemic.
    Fernández Pozo R; Wilby MR; Vinagre Díaz JJ; Rodríguez González AB
    Cities; 2022 Aug; 127():103723. PubMed ID: 35530724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.